Equity financing and public offering

ZAG-S&W’s Corporate and Capital Markets department is one of the leading practices in its field in Israel and also enjoys international recognition for its extensive experience in equity financing and public offerings for a range of clients. The department is consistently ranked in the top-tier by prominent local and international legal guides. 


Clients
These clients include public companies in the life sciences sector, with a particular emphasis on medical devices, pharmaceuticals, biotechnology and medical IT, as well as founders, investors, underwriters and many private and public companies listed in Israel and the United States.

The team
The Corporate and Capital Markets department comprises seasoned and experienced attorneys with a deep understanding of the complexities of corporate and securities law. Our attorneys apply their profound understanding of these laws to the various stages of a company's lifecycle, from incorporation to going public, expanding internationally or reaching the "exit."


In addition to legal advice, our attorneys also provide the firm’s clients with ongoing business advice, on issues such as: choosing partners, deal structuring, building strategic engagements and day-to-day management.

In recent years, the department has handled numerous complex equity financings and public offerings for many companies, including:

Medical device companies (Endospan, IceCure, Mazor Robotics Ltd. and Ossio)

Pharmaceutical companies (PolyPid Ltd. and Alcobra Pharma)

Clinical stage biopharmaceutical companies (Silenseed Ltd. and Raziel Therapeutics), biotechnology and biomedical companies (Syqe Medical, Insuline Medical Ltd., Kamedis Ltd. and Pluristem Therapeutics, Inc.)